IgE and D‐dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria

Recently, it has been demonstrated that IgE levels may predict the clinical response to omalizumab treatment in chronic spontaneous urticaria (CSU) patients1 . The authors showed that baseline total IgE levels and notably the ratio between their levels at week 4 of treatment and baseline are predictors of response to omalizumab in CSU1 . In another recent study, IgE levels before treatment have been shown to be inversely proportional to CSU relapse time after omalizumab discontinuation2 . This article is protected by copyright. All rights reserved.